Genentech is gearing up for the launch of ocrelizumab (humanized rituximab) for relapsing/remitting MS. Get your resume's ready... should coincide nicely with the Sept 15th vesting schedule.
There are about 6 companies either building new salesforces in neuro, neph, and other specialties that coincide exactly with the vesting date. The turnover will be massive.
